Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07313384

Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy

The DINE-GLP1 study aims to understand how people on GLP-1 therapy change their eating habits and what kind of dietary support they need. As more people use GLP-1 medications, there's not much guidance on what they should eat, mostly just focusing on managing symptoms and cutting calories. Since these medications reduce food intake, it's important to ensure the diet is nutritious even with fewer calories to help with long-term weight control and health. Most research has looked at how the body responds to the medication and whether patients take it as prescribed, but not much is known about what patients actually experience, what they think they need, or how they could use additional support. Understanding patients' views can help create better lasting solutions. Note that this study does not provide free GLP-1 medication.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Obesity Type 2 Diabetes Mellitus Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity (Disorder) Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University South Carolina, Columbia, South Carolina, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 and older
  • Recently has been prescribed GLP-1 therapy for the treatment of obesity or T2DM but have not yet initiated the medication
  • Has regular access to a smartphone and internet to complete short surveys and food recalls online
  • Willing to sign informed consent.

Exclusion criteria

  • Already began the GLP-1 medication
  • Have medical concerns making participation unsafe

Treatment and study plan

GLP-1 therapy

Drug

Exposure to GLP-1 Therapy for obesity or T2DM management.

Primary outcomes

  1. Change in Healthy Eating Index

    Time frame: Baseline and 12-weeks

    The Healthy Eating Index (HEI) is a scoring metric developed by the U.S. Department of Agriculture (USDA) and the NCI to assess how well a person's diet conforms to the Dietary Guidelines for Americans. It evaluates the consumption of 13 dietary components, including both adequacy (foods to increase) and moderation (foods to decrease). The scores range from 0 to 100. An ideal overall HEI score of 100 reflects that the set of foods aligns with key dietary recommendations and dietary patterns published in the Dietary Guidelines.

Secondary outcomes

  1. Change in Body Weight

    Time frame: Baseline and 12 weeks

    Change from Baseline in Body Weight at 12-weeks

Sponsors and collaborators

Lead sponsor

University of South Carolina

Other

Collaborators

  • Prisma Health-Upstate

Registry information

Acronym: DINE-GLP1

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 31, 2025
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.